A la República Democràtica del Congo, la verola del mico causa la mort de milers d' infants.
El nostre equip fem tots els esforços per aturar l' epidèmia.
🩺🌍
🤰 Can we safely treat malaria in pregnancy with Pyramax?
The PYRAPEG-extended project evaluated the safety and efficacy of Pyramax for treating malaria in pregnancy in 5 African countries.
More 👉 https://t.co/LCOcehKAwk
Our latest research on Intermittent screening using ultra‑sensitive
malaria RDT and treatment with pyronaridine‑artesunate compared to standard preventive ttt with SP for malaria prevention in pregnant women in Kin, DRC has just been published. Read here: https://t.co/exPc7mubmE
📢CEPI has today announced funding for a new trial set to evaluate @BavarianNordic’s mpox vaccine in pregnant and breastfeeding women, and infants under two, in the Democratic Republic of Congo. (1/6)
➡️https://t.co/W3cP3p7ixw
It was an honor to have a conversation together with Prof. @oriolmitja for The Lancet podcast, discussing about the current Mpox outbreak
@Tropmedunikin@Unikinrdc@TheLancet
🔗 to the audio ⤵️
https://t.co/v1N9JcXDgI
.@HypoliteMavoko's work doesn’t stop there. He has also published his experience of conducting clinical trials in Boende, shining a light on the high-quality research conducted in the region 🔬
https://t.co/3QqKqlHvdD
From 9th to 10th March 2023, the University of Amsterdam hosted the PYRAPREG investigators’ meeting, to discuss project progress and perspectives. The Consortium appreciated the valuable contributions to the discussions, brought by the representatives of EDCTP, MMV and Clinapharm